Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.50
Bid: 43.00
Ask: 44.00
Change: 3.00 (7.41%)
Spread: 1.00 (2.326%)
Open: 40.50
High: 45.00
Low: 40.50
Prev. Close: 40.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

Thu, 04th Apr 2024 17:24

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Artemis Resources Ltd - gold, copper and lithium-focused exploration company with projects in Western Australia - Updates on Karratha gold project exploration programme in West Pilbara, Western Australia. Says Lulu Creek will be drill tested in the third quarter of 2024. Adds that programme of works is submitted and approved, with heritage clearance application underway.

----------

Develop North PLC - investor in residential and commercial property sector - Starts share buyback programme of up to GBP500,000. The programme is set to end on June 30 and could be terminated earlier.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Raises GBP51,670 via issuing 5.2 million retail offer shares at a price of 1 pence each. Applies to the London Stock Exchange for the admission of a total of 152.5 million new shares to trading on AIM, comprising of 79.4 million placing shares, 5.6 million subscription shares and 62.3 million initial consideration shares

----------

Genflow Biosciences PLC - London-based biotechnology company focused on longevity - Raises GBP715,000 via its broker Capital Plus Partners by placing 57.2 million shares. Chief Executive Officer Eric Leire invested GBP50,000 personally in the placing, the company says.

----------

Insig AI PLC - London-based data science and machine learning firm - Agrees to a GBP250,000 equity funding facility with Executive Chair Richard Bernstein, which will allow him to subscribe for up to around 1.3 million new shares at 20 pence per share until the end of August.

----------

Northcoders Group PLC - Manchester-based software coding training provider - Launches part-time business-to-costumer software development bootcamp that aims to make careers in tech more accessible. The virtual course will start in mid-July and has been created due to demand for alternative structures, Northcoders says. Chief Executive Officer Chris Hill says: "Not only is this in line with the group's strategy to address the nation's widening digital skills, but it embodies our commitment to inclusivity and flexibility, ensuring that anyone who is interested in the opportunity to work in the ever-growing UK technology market can pursue their ambitions, regardless of their schedule or background."

----------

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Raises GBP1.2 million via issuing 11.7 million fundraising shares at the placing price of 10p per share.

----------

Schroder BSC Social Impact Trust PLC - investment firm focused on positive social impact as well as long-term capital growth and income - Announces GBP5 million commitment to Savills IM Simplify Affordable Homes Ltd Partnership, which will lie within Schroder's High Impact Housing asset class allocation. "The UK continues to face a housing crisis with an acute lack of social and affordable housing and this fund will deliver homes for lower income households and people currently in need of social housing in areas in most need. The SAH management team have a strong track record, with over 30 years' expertise and deep sector knowledge with long standing housing association relationship. We believe they are well-placed to deliver high quality financial and impact returns through providing affordable housing at-scale," says Jeremy Rogers, chief investment officer of Big Society Capital, portfolio manager of Schroder BSC.

----------

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 Jun 2012 13:59

Small caps round-up: Cyan, Aer Lingus, Mobile Tornado ...

Cyan Holdings, the wireless solutions company, has revealed that three more Cyan partners have received requests from the Tamil Nadu Electricity Board (TNEB) Automatic Meter Reading tender to proceed with installation and commissioning of 500 unit pilots within the next 25 days. The news follows Cya

Read more
6 Jun 2012 14:22

Small caps round-up: PLUS Markets, Sareum, Planet Payment

PLUS Markets Group, which provides listing and quoting services to around 140 companies on the stock exchange, has recommended its shareholders to vote in favour of the proposed disposal of its PLUS-SX division to ICAP for a nominal sum at its general meeting on June 18th. 'The disposal will, theref

Read more
27 Feb 2012 14:57

Sareum confident of at least one deal in 2012

Penny stock Sareum, which develops drugs to combat cancer, saw its losses widen in the second half of 2011, in line with the board's expectations. The firm's losses after tax deepened from £0.26m to £0.33m, which the firm said reflects an increase in research and development. Pre-tax losses totall

Read more
15 Aug 2011 11:50

Cancer results boost Sareum

Cancer drug discovery business Sareum shot ahead after it said it had selected a "preclinical development candidate" from research into Chk1, a method of controlling a cancer cells' response to DNA damage. The candidate, when orally dosed, reduces cancer growth rates compared to treatment with the

Read more
4 Mar 2011 11:08

Sareum soars after colon cancer study

Shares in Sareum were soaring after the cancer drug discovery business announced positive results from a study into colon cancer. The study, which was conducted by the Institute of Cancer Research, founded that Sareum's Chk1 inhibitor, used alongside a gemcitabine, a chemotherapeutic, "demonstrate

Read more
21 Feb 2011 15:56

Sareum narrows losses

Sareum, the cancer drug discovery business that earlier this month shot up after announcing positive results from a leukaemia study, narrowed losses in the half year to 31 December. Pre-tax losses narrowed to £281,000 from £321,000 over the same period a year ago. "Recent fundraisings provide us w

Read more
7 Feb 2011 11:52

Small caps round-up: Henry Boot, Firestone Diamonds, Amino Tech...

Property developer Henry Boot says it will move to a net cash position after it agreed the sale of a shopping centre in Ayr for £33.8m and the sale of land with planning permission to build houses in Buckingham for an undisclosed fee. Henry Boot said last month that one of its goals is to 'manage d

Read more
16 Mar 2010 10:50

Small caps round-up: Amphion, Bioquell, Ablon...

Shares in Amphion Innovations jumped after the medical and technology sector said it was cautious but confident in the strength of its model following a year which saw revenue increase to $8.6m from $7.1m in 2008, but losses increase to $2.9m from $1.8m. Shares in Bioquell moved in the other direct

Read more
20 Jan 2010 13:10

Small caps round-up: ING Real, Intellego, Oxford Intruments...

ING UK Real Estate Income Trust will repay £15m of debt through the purchase and cancellation of loan notes at a discount to nominal value in two separate transactions. The transaction will result in a one off gain to NAV expected to be in the order of £680,000, and will also save over £719,000 per

Read more
27 Oct 2009 11:09

Small caps round-up: Ariana, Gemfields, Sareum

Turkey-focused gold miner Ariana Resources has set up a 50:50 joint venture to combine its two main projects, Sindirgi and Tavsan, into a single conceptual entity. The company confirmed its partner in the 'Red Rabbit' project as Turkish turn-key construction firm Proccea Construction. "A Memorandu

Read more
6 Oct 2009 09:47

Small caps round-up: ProStrakan, Sareum,Sirius

Speciality pharmaceutical company ProStrakan's New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA). Subject to successful completion of the US approval process, the Scottish firm plans to launch Abstral, which helps ease pain for

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.